PCM
ATRC icon

Portolan Capital Management’s AtriCure ATRC Stock Holding History

Portolan Capital Management’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-297,592
Closed -$5.82M – 124
2016
Q4 		$5.82M Buy
297,592
+48,174
+19% +$873K 0.78% 49
2016
Q3 		$3.95M Buy
+249,418
New +$3.83M 0.54% 65

Other funds holding ATRC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Portolan Capital Management's ATRC Position: Q1 2017 in Review

Portolan Capital Management sold out of AtriCure (ATRC) in Q1 2017, closing a stake of 297,592 shares — an estimated $5.82M sold.

Portolan Capital Management first reported a position in ATRC in Q3 2016 and held it in 2 quarters. The position peaked at $5.82M in Q4 2016. 99 funds tracked by Wall St. Rank hold ATRC as of Q1 2017.

  • Portolan Capital Management reported no remaining AtriCure position as of Q1 2017 after selling out during the quarter.
  • Portolan Capital Management sold 297,592 AtriCure shares in Q1 2017, an estimated $5.82M.
  • Portolan Capital Management first reported a position in AtriCure in Q3 2016 and held it in 2 quarters.
  • Portolan Capital Management's AtriCure position peaked at $5.82M in Q4 2016.
  • 99 funds tracked by Wall St. Rank held AtriCure as of Q1 2017.

Based on Portolan Capital Management's 13F filing for Q1 2017, filed 15 May 2017.